Also see: RIM, Devon, Aetna: Analysts' New Ratings
Editor's Note: Green and red arrows refer to intraday stock price movement.
NEW YORK (
STOCK COMMENTS / EPS CHANGES
estimates upped at Morgan Stanley through 2013, Morgan Stanley said. Company can continue to grow iPhone and tablet sales, especially in China. Overweight rating and $410 price target.
estimates boosted at Credit Suisse. ACN 2011 and 2012 EPS estimates raised to $3.28 and $3.74, respectively. Stellar 2Q11 results across the board, Credit Suisse said. Maintain Outperform rating.
estimates, target raised at Goldman. Shares of ACN now seen reaching $64, according to Goldman Sachs. Estimates also increased, given higher enterprise IT demand. Buy rating.
Cabot Oil & Gas
numbers boosted at Morgan Stanley. Shares of COG now seen reaching $60, according to Morgan Stanley. Estimates also upped, as Marcellus should continue to drive growth. Overweight rating.
estimates upped at UBS through 2012, UBS said. Company is keeping costs low and realizing a lower tax rate. Neutral rating and $16 price target.
estimates, target reduced at Ticonderoga. Shares of GHL now seen reaching $52, according to Ticonderoga Securities. Estimates also cut, as the company is realizing a slower start to 2011. Sell rating.
target boosted at UBS. Shares of LO now seen reaching $102, according to UBS. FDA is not likely to pursue a ban on menthol cigarettes. Buy rating.
price target boosted at Credit Suisse to $18 from $16. News Corp's pursuit of BSkyB nearing its final stages, Credit Suisse said. Maintain Neutral rating.
price target higher at Credit Suisse, to $42 from $38. Strong overall 3Q11 results, Credit Suisse said. 2011 and 2012 EPS estimates raised to $2.11 and $2.38, respectively. Maintain Outperform rating.
estimates, target raised at UBS. Shares of ORCL now seen reaching $39, according to UBS. Estimates also increased, to match the company's new guidance. Buy rating.
estimates, target increased at Goldman. PAYX estimates were raised through 2013, Goldman Sachs said. SurePayroll acquisition should help boost margins. Sell rating and new $27 price target.
estimates lowered at Oppenheimer. QCOM estimates were cut through 2012, Oppenheimer said. Company could be hurt in the near-term because of Japan. Outperform rating and $60 price target.
Research in Motion
estimates increased at UBS through 2013, UBS said. Company is realizing a lower tax rate. Neutral rating and $63 price target.
estimates cut at Oppenheimer through 2012, Oppenheimer said. Company could continue to face pressure from Japan and NOK. Outperform rating and $9 price target.
estimates reduced at Oppenheimer through 2012, Oppenheimer said. Japan could hurt near-term results. Outperform rating and $34 price target.
End of report.
This article was written by a staff member of TheStreet.